Saxenda (Liraglutide) is a new prescription weight loss drug for the treatment of clinical obesity. Saxenda is manufactured by Novo Nordisk. The active ingredient in Saxenda is Liraglutide. Liraglutide works by imitating the effects of glucagon-like peptide ("GLP-1"), a hormone produced in the intestines that signals to the brain when you are full. The drug essentially suppresses appetite by tricking the brain.
Liraglutide has been approved since 2010 for use in the treatment of diabetes under the brand name Victoza. Victoza has already been tagged as a potential caused of pancreatic cancer. According to reports published by the FDA, Victoza was a suspected cause of more than 300 deaths and over 3,000 hospital visits between 2010 and 2014. Around 1/3 of those fatalities were the result of pancreatic cancer.
Hundreds of Victoza lawsuits have already been filed. It makes sense Victoza would go first because it is an older drug. But, if you believe the science that plaintiffs' lawyer are adopting, Saxenda may cause a greater cancer risk because it contains a much higher dose of Liraglutide than Victoza. As a result, interest in Saxenda cancer lawsuits is quickly increasing.Growing Concerns Regarding Saxenda and Other Incretin Drugs
The active ingredient in Saxenda and Victoza (Liraglutide) is part of the "incretin" family of drugs. Incretin drugs fall into 2 categories: (1) GLP-1 agonists such as Saxenda and Victoza; and (2) DPP-4 inhibitors like Januvia. What all incretin drugs have in common is that they manipulate GLP-1 hormone levels in the body. The underlying problem with incretin drugs is that they are known to cause abnormal cell growth in the pancreas. Since incretin drugs first came on the market there has been a growing tide of concern that the effect of these drugs on the pancreas may cause pancreatic cancer.
The first incretin drugs were approved by the FDA in 2005 for treatment of diabetes. By 2007 the FDA had received numerous reports that these drugs were causing pancreatitis (inflammation of the pancreas). This prompted the FDA to publish an alert warning that use of incretin drugs may increase the risk of acute pancreatitis. The FDA also required the drug manufacturers to include this information their product information and warnings. The next round of incretin drug approvals resulted in a similar wave of reports regarding pancreatitis.
In 2009 a study of incretin drugs was conducted on animals. The results of the study indicated that increased GLP-1 levels were a probable cause of pancreatic and thyroid cancer in rodents.
Researchers at UCLA Medical School later conducted a study which autopsied individuals who had been taking incretin drugs. The autopsy results showed cell abnormalities in the pancreases of ALL of the individuals who had been taking incretin drugs for a year of more. In additional to abnormal cell counts, small tumors were notes in the pancreases of the individuals taking incretin drugs. The cell abnormalities and tumors are indications that these individuals may have developed pancreatitis (an inflamed pancreas) or pancreatic cancer in the future.
In 2011 a study was published in the Journal of Gastroenterology on the incretin drug Byetta. The study found that individuals on Byetta were 3 times more likely to get pancreatic cancer. In 2013 a study conducted by Johns Hopkins found that incretin drugs double the risk of acute pancreatitis and that individuals taking the drugs had a higher rate of pancreatic masses and precancerous tumors.
A few months later a European study also concluded that there was an association between incretin drugs and pancreatic damage. In 2012 the FDA received a Citizen Petition formally requesting that Saxenda's sister drug, Victoza, be taken off the market based on evidence of an increased risk of pancreatic cancer. In response the FDA issued a Drug Safety Communication in March 2013 regarding incretin drugs and pancreatic cancer risks.
The FDA then undertook an investigation into the issue of pancreatic cancer and incretin drugs. In March 2014 the FDA announced that there was not conclusive evidence to show a causal link between Victoza and pancreatic cancer. A few months later the FDA reviewed safety concerns regarding Saxenda and reached the same conclusion. In 2017 the results of a new European study were presented to the European Cancer Organization. This study concluded that individuals taking incretin drugs for diabetes were at a significantly increased risk of developing pancreatic cancer.Saxenda Litigation
Saxenda is a relatively new drug having only been on the market for a few years. As a result, this litigation is not of the ground. Saxenda's sister drug, Victoza, has been around a few years longer, however, and is already the subject of numerous cancer injury lawsuits. Saxenda and Victoza contain the same active ingredient (Liraglutide) but Saxenda is a much higher dosage so it presumably presents the same if not greater safety risks.
The Victoza lawsuits are based on failure to warn allegations. Specifically, that Novo Nordisk failed to warn doctors and patients that Victoza increased the risk of pancreatic cancer. Like Victoza, Saxenda comes with a so-called "Black Box" warning label - the FDA's highest level warning. The label warns about the risk of thyroid cancer and a potential risk of acute pancreatitis. However, there is no specific mention of an increased risk of pancreatic cancer.Contact Us About Saxenda
If you or someone you love has been harmed by Saxenda, call Miller & Zois at 800-553-8082 or click here for a free online consultation.